Colin Bader
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Colin Bader has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Caroline Machado Kopruszinski
Department of Pharmacology, College of Medicine—Tucson, University of Arizona, Tucson, AZ, United States
1 shared publication - Catherine Daniela Chong
Department of Neurology Mayo Clinic Phoenix Arizona USA
1 shared publication - David W. Dodick
Atria Academy of Science and Medicine, New York, NY, United States
1 shared publication - Edita Navratilova
Department of Pharmacology, Arizona Health Sciences Center, University of Arizona, Tucson, AZ, USA
1 shared publication - Frank Porreca
Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ, United States
1 shared publication - Gina Dumkrieger
Department of Neurology Mayo Clinic Phoenix Arizona USA
1 shared publication
Latest Publications
- 23 September 2026
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (11) , e487-e501
Clinical and preclinical investigation of the mechanism promoting aura in post-traumatic headache and inhibition of pain-related behavior in mice by onabotulinumtoxinA
Post-traumatic headache (PTH) is the most common consequence of mild traumatic brain injury (mTBI) and often resembles migraine. In 20% to 30% of migraine patients, headaches are preceded by aura, transient visual or sensory disturbances, which are caused by cortical spreading depression (CSD) that can induce headache pain. However, whether mTBI promotes the development of aura and CSD and their possible contributions to PTH remains unclear. We examined the incidence of new-onset aura in individuals with PTH who had no history of aura. Thirty-two percent (35/108) developed new aura symptoms within 60 days of injury, suggesting that mTBI can sensitize the cortex to the induction of CSD. To test this, we combined electrophysiology, neuroimaging, and behavioral assays in a mouse model of mTBI-induced PTH. After closed-head mTBI, injured mice exhibited a 160% increase in CSD induction probability (ie, lowered threshold) and became sensitized to CSD induction by brief exposure to stress, a common headache trigger. When evoked optogenetically, CSD produced prolonged periorbital and hind paw allodynia, consistent with headache-like pain. Subcutaneous onabotulinumtoxinA administered to the scalp after mTBI did not alter CSD susceptibility but completely abolished optogenetic CSD-induced allodynia. These findings suggest that mTBI elicits sensitization to CSD induction and promotes the emergence of aura in humans, likely contributing to PTH. It is important that, even after mTBI-induced sensitization, onabotulinumtoxinA decoupled CSD from pain behaviors, suggesting efficacy in treating PTH associated with aura.
- 23 September 2026
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (11) , e487-e501
Clinical and preclinical investigation of the mechanism promoting aura in post-traumatic headache and inhibition of pain-related behavior in mice by onabotulinumtoxinA
Post-traumatic headache (PTH) is the most common consequence of mild traumatic brain injury (mTBI) and often resembles migraine. In 20% to 30% of migraine patients, headaches are preceded by aura, transient visual or sensory disturbances, which are caused by cortical spreading depression (CSD) that can induce headache pain. However, whether mTBI promotes the development of aura and CSD and their possible contributions to PTH remains unclear. We examined the incidence of new-onset aura in individuals with PTH who had no history of aura. Thirty-two percent (35/108) developed new aura symptoms within 60 days of injury, suggesting that mTBI can sensitize the cortex to the induction of CSD. To test this, we combined electrophysiology, neuroimaging, and behavioral assays in a mouse model of mTBI-induced PTH. After closed-head mTBI, injured mice exhibited a 160% increase in CSD induction probability (ie, lowered threshold) and became sensitized to CSD induction by brief exposure to stress, a common headache trigger. When evoked optogenetically, CSD produced prolonged periorbital and hind paw allodynia, consistent with headache-like pain. Subcutaneous onabotulinumtoxinA administered to the scalp after mTBI did not alter CSD susceptibility but completely abolished optogenetic CSD-induced allodynia. These findings suggest that mTBI elicits sensitization to CSD induction and promotes the emergence of aura in humans, likely contributing to PTH. It is important that, even after mTBI-induced sensitization, onabotulinumtoxinA decoupled CSD from pain behaviors, suggesting efficacy in treating PTH associated with aura.